Peter Heerma insider trades: Travere Therapeutics (TVTX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Peter reports to the SEC
Open-market buys and sales
24 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | TVTX | ↓ Sell | 283,189 | $63.06 | $17.9M | Direct | Sep 17, 2026 (0d) |
| May 5, 2026 | TVTX | ↓ Sell | 2,174 | $46.65 | $101K | Direct | May 6, 2026 (1d) |
| Apr 14, 2026 | TVTX | ↓ Sell | 7,215 | $41.93 | $303K | Direct | Apr 15, 2026 (1d) |
| Feb 3, 2026 | TVTX | ↓ Sell | 7,310 | $32.12 | $235K | Direct | Feb 3, 2026 (0d) |
| Oct 31, 2025 | TVTX | ↓ Sell | 5,591 | $35.00 | $196K | Direct | Nov 4, 2025 (4d) |
| Oct 28, 2025 | TVTX | ↓ Sell | 2,662 | $30.00 | $80K | Direct | Oct 30, 2025 (2d) |
| May 5, 2025 | TVTX | ↓ Sell | 1,771 | $21.05 | $37K | Direct | May 5, 2025 (0d) |
| Feb 12, 2025 | TVTX | ↓ Sell | 5,642 | $24.33 | $137K | Direct | Feb 12, 2025 (0d) |
| Feb 3, 2025 | TVTX | ↓ Sell | 5,166 | $20.12 | $104K | Direct | Feb 4, 2025 (1d) |
| Jan 22, 2025 | TVTX | ↓ Sell | 1,584 | $18.94 | $30K | Direct | Jan 23, 2025 (1d) |
| Sep 9, 2024 | TVTX | ↓ Sell | 2,191 | $11.52 | $25K | Direct | Sep 9, 2024 (0d) |
| Feb 1, 2024 | TVTX | ↓ Sell | 4,195 | $8.53 | $36K | Direct | Feb 2, 2024 (1d) |
| Jan 23, 2024 | TVTX | ↓ Sell | 1,559 | $9.07 | $14K | Direct | Jan 25, 2024 (2d) |
| Oct 3, 2023 | TVTX | ↓ Sell | 3,091 | $8.25 | $26K | Direct | Oct 4, 2023 (1d) |
| Feb 1, 2023 | TVTX | ↓ Sell | 1,779 | $21.75 | $39K | Direct | Feb 2, 2023 (1d) |
| Jan 24, 2023 | TVTX | ↓ Sell | 1,550 | $21.90 | $34K | Direct | Jan 26, 2023 (2d) |
| Oct 4, 2022 | TVTX | ↓ Sell | 3,042 | $25.68 | $78K | Direct | Oct 6, 2022 (2d) |
| Jan 31, 2022 | TVTX | ↓ Sell | 1,125 | $27.40 | $31K | Direct | Feb 2, 2022 (2d) |
| Jan 24, 2022 | TVTX | ↓ Sell | 1,875 | $24.98 | $47K | Direct | Jan 26, 2022 (2d) |
| Oct 4, 2021 | TVTX | ↓ Sell | 3,058 | $24.77 | $76K | Direct | Oct 5, 2021 (1d) |
| Aug 17, 2021 | TVTX | ↓ Sell | 1,407 | $17.12 | $24K | Direct | Aug 17, 2021 (0d) |
| Feb 8, 2021 | TVTX | ↓ Sell | 2,250 | $31.50 | $71K | Direct | Feb 9, 2021 (1d) |
| Feb 3, 2021 | TVTX | ↓ Sell | 1,126 | $29.83 | $34K | Direct | Feb 3, 2021 (0d) |
| Oct 5, 2020 | RTRX | ↓ Sell | 4,376 | $19.13 | $84K | Direct | Oct 5, 2020 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TVTX insiders
Open-market trades in the last 12 months
About Peter Heerma's insider trades
Peter Heerma is EVP, Chief Commercial Officer at Travere Therapeutics (TVTX). Since Oct 5, 2020, Peter has reported no open-market purchases and 24 sales worth $19.7M on SEC Form 4. In the last 12 months: 4 sales ($18.5M).
Their filings also include grants and awards (13 filings), option exercises (4 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TVTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.